A rapid and precise immunoassay for quantification of total homocysteine in blood samples is presented. The method avoids the use of radioisotopes and chromatographic separations and relies on enzymatic conversion of homocysteine to S-adenosyl-L-homocysteine, followed by quantification of S-adenosyl-L-homocysteine by an enzyme-linked immunoassay in microtiter format. The within-and between-assay imprecision is <6% and 8%, respectively, and results by the method show good correlation with those by HPLC. Including controls and calibrators in duplicates, 82 samples can be analyzed within 2.5 h. The procedure can be fully automated.
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The concentration of total homocysteine (tHcy) 3 in plasma or serum is an established marker of common diseases. It is a strong and independent risk factor for cardiovascular disease, a sensitive marker of cobalamin and folate deficiencies, and is used to diagnose the inborn errors in metabolism termed homocystinuria [1] [2] [3] [4] . The tHcy concentrations have also been related to birth defects in pregnant women and to cognitive impairment in the elderly. Thus, the diagnostic utility of tHcy determinations is well documented in several clinical conditions, and the establishment of a tHcy assay is warranted in medium to large routine clinical chemistry laboratories. However, the current assays, based on HPLC or GC-MS, are time consuming and expensive and require highly skilled technical staff, and so are not an option for routine clinical chemistry laboratories.
We present here a new method that allows fully automated analysis of tHcy, avoiding the use of radioisotopes and tedious chromatographic separations. The method is based on enzymatic conversion of Hcy to S-adenosyl-l-homocysteine (SAH) by the action of SAH hydrolase (SAHase; EC 3.3.1.1), followed by quantification of SAH in a competitive immunoassay with use of a monoclonal anti-SAH antibody [5] . This principle has been used in an automated tHcy assay on the Abbott IMx instrument [6] . The method presented here, however, is not limited to specialized equipment, but allows the use of this technology in different formats and on various analytical platforms.
Materials and Methods materials
Apparatus. A Multiscan RC microtiter reader (Labsystems OY) was used to measure absorbances on the microtiter plates. The microtiter plates ("Maxisorp" from A/S Nunc) were washed with a Well Wash 4 washing machine (Denley Instruments, Billinghurst, UK).
Chemicals. SAH, casein, bovine serum albumin (BSA), Tween 20, l-dithiothreitol (DTT), thimerosal, NaN 3 , d,lhomocysteine, l-cysteine, and l-methionine were purchased from Sigma Chemical Co. l-Cystathionine and SAM were purchased from Fluka Chemie. For comparison, we obtained l-homocystine from both Sigma and Fluka; the Sigma product was the one generally used. Merck provided Na 2 HPO 4 , NaCl, NaOH, NaF, citric acid, and sulfuric acid. Bovine ␥-globulin was provided by Miles Inc. SAHase was obtained from bovine liver by an in-house purification procedure. Adenosine (Ado) and adenosine deaminase (Adoase) were purchased from Boehringer Mannheim.
The monoclonal mouse anti-SAH antibody used was provided by Abbott Labs. Horseradish peroxidase (HRP)-conjugated rabbit anti-mouse antibody was from Dako. Tetramethylbenzidine (TMB/E) solution from Chemicon International Inc. (Temecula, CA) was used as peroxidase substrate. The microtiter plates used in the assay were precoated with a BSA-SAH conjugate made by Axis Nord.
Reagents. The assay relies on two buffers: assay buffer 1, which contains 100 mmol/L Na 2 HPO 4 , 150 mmol/L NaCl, and 14 mmol/L NaN 3 , adjusted to pH 8.5; and assay buffer 2, which is 100 mmol/L Na 2 HPO 4 , 150 mmol/L NaCl, and 0.1 g/L thimerosal, to which is added, after adjustment to pH 7.4, 0.1 g/L bovine ␥-globulin, 2 g/L BSA, and 0.5 mL/L Tween 20.
Assay buffer 1 diluted 1:10 in water is used as washing solution in all washing steps.
Coating of microtiter plates. To each well of the microtiter plate is added 250 L of coating solution containing 0.5 mg/L SAH-BSA conjugate and 2 mg/L Hcy-stripped BSA dissolved in 10 mmol/L Na 2 HPO 4 and 150 mmol/L NaCl, adjusted to pH 7.4. After incubation overnight at 4°C, the plates are emptied by inversion. Then 300 L of blocking solution (25 g/L sodium caseinate in 10 mmol/L Na 2 HPO 4 and 150 mmol/L NaCl, adjusted to pH 7.4) is added to each well, and the plates are incubated overnight at 4°C. Finally, the plates are washed 3 times with 400 L of washing solution and dried by inversion on absorbent paper.
assay method
Principle. The Hcy in serum/plasma samples is mainly in protein-bound form [7, 8] . Adding DTT to the sample cleaves disulfides, mixed disulfides, and protein-bound Hcy, releasing the free, reduced form of Hcy. Use of SAHase and excess Ado converts the reduced Hcy to SAH, as illustrated in Fig. 1 , and tHcy in the sample is determined as SAH in a competitive immunoassay with an anti-SAH antibody. Fig. 2 depicts each step in the assay procedure. As part of sample pretreatment before the immunoassay step, any excess Ado remaining after the Hcy is converted is removed by Adoase, which avoids interference by Ado in the succeeding step. Because of the reversible nature of the SAHase reaction shown in Fig. 1 , thimerosal, an inhibitor of SAHase, is included to prevent hydrolysis of SAH back to Hcy when the Ado is removed. The enzyme-treated samples are transferred to immunoplates coated with BSA-SAH and a competitive immunoassay for SAH is run.
The enzyme assay. Before start of the analysis, we made up a "sample preparation solution," sufficient for 35 sam- For comparison, all samples were also analyzed for tHcy by HPLC at the University of Bergen [9] . 
blood samples
Whole blood was collected into evacuated blood-collecting tubes without additives (for preparation of serum), or containing EDTA, heparin, or citrate as anticoagulants (for preparation of plasma). Blood tubes containing the stabilizer NaF with or without heparin were also evaluated. The samples were kept cold (Ͻ4°C) after collection and centrifuged within 1 h after sampling. The serum and plasma supernatant were transferred to new vials and stored at Ϫ20°C until analyzed.
Results
Calibration curve. A representative dose-response curve constructed with SAH calibrators is shown in Fig. 3 . Calibrators were always run in duplicate. Although some variation is seen, the calibration curves made from SAH or crystalline l-homocystine are superimposed (see Discussion). Samples with Hcy concentrations between 2 and 50 mol/L can be determined by the assay without additional dilution. Samples with tHcy Ͼ50 mol/L should be diluted in assay buffer 1.
Linearity and recovery. Table 1 lists the results for analysis of dilutions of a sample with high Hcy concentration (40.7 mol/L, as determined by HPLC [9] , and then diluted in assay buffer 1). Linear regression of the observed tHcy (y) vs the calculated expected tHcy (x) gave the following: y ϭ 1.04x Ϫ 2.25 (r ϭ 0.996, S y͉x ϭ 1.05).
Recovery of known amounts of SAH added to samples is shown in Table 2 . Because crystalline l-homocystine gave lower recovery and less consistent results than SAH, Hcy plasma samples (with tHcy concentrations Ͼ80 mol/L) were also used. A summary of the results obtained with either SAH or l-homocystine (crystalline/ blood samples) in the recovery experiments is presented in Table 3 . 
Clinical Chemistry
Precision and comparison of methods. Table 4 lists betweenand within-assay imprecision of the method. The withinassay variation was estimated after analyzing three samples containing 8.1, 13.6, and 27.3 mol/L tHcy in 21 parallel determinations. Each of the samples were assayed in duplicate in the immunoassay step to test the imprecision of this step separately. The between-assay variation was estimated from results for 21 successive analytical set-ups.
A comparison of the results obtained with the method presented here (y) and those of an HPLC method [9] (x) indicatedgoodagreementbetweenthetwomethods (Fig.4) .
Specificity and interfering compounds.
The cross-reactivity of the monoclonal SAH antibody against potentially interfering compounds was tested by adding those compounds to the calibrators. The compounds and concentration intervals tested (given as final concentration when added to the calibrators) were: cysteine (0 -3 mmol/L), SAM (0 -1 mmol/L), cystathionine (0 -0.13 mmol/L), methionine (0 -5 mmol/L), and Ado (0 -50 mol/L). In addition, these compounds, at concentrations of 30, 10, 1.3, 50, and 1 mmol/L, respectively, were also assayed as samples. Except for the SAM, none of the tested compounds affected the calibration curve. When assayed as samples, the concentrations recorded as tHcy were all Ͻ0.5 mol/L. Again, SAM was the only compound found to substantially affect the performance of the assay; when present in samples at Ͼ10 mol/L, it led to falsely increased results for Hcy concentrations (see Discussion).
Anticoagulants and stabilizers. As long as the samples were treated as described in Materials and Methods, the tHcy concentrations were nearly the same (Ͻ6% difference) in serum and plasma, independent of type of anticoagulant. To test the effect of fluoride as a stabilizer [11, 12] in blood sample tubes, NaF was added to the sample to a concentration of 8 g/L (twice that ordinarily used in sample collection tubes) without affecting the assay results. However, plasma from vials with added fluoride/heparin showed ϳ10% lower tHcy concentration than the corresponding EDTA-plasma samples. No differences were found when using vials with added citrate and heparin; however, the number of samples used was limited, and more-thorough studies need to be done.
Discussion
Most methods for determining tHcy in serum or plasma are time-consuming and cumbersome [8, 9, 13] . With the present method, 82 samples, 2 controls, and 6 calibrators (controls and calibrators in duplicate) can be analyzed in ϳ2.5 h. Multiple plates can be analyzed simultaneously without much extra effort or, alternatively, the method can be partially or fully automated by using appropriate robotic equipment. The method has acceptable precision (CV Ͻ6 -8%), has sufficient analysis range for most clinical applications, and shows good correlation with an established HPLC technique. Thus, this assay may be an acceptable option for routine clinical chemistry laboratories.
For tHcy concentrations within the range of the calibration curve, i.e., 2-50 mol/L, the enzymatic conversion to SAH is complete, as illustrated by the superim- The samples were run in 21 duplicates. Between-assay variation is based on results from 21 succeeding analytical set-ups performed over 3 days.
posed calibration curves derived from l-homocystine and SAH. However, similar to what was seen in the recovery experiments utilizing crystalline l-homocystine, there was also some variability of the dose-response curve prepared with crystalline l-homocystine, particularly in the lower concentration range. Because of the good recovery achieved when plasma samples with high tHcy concentrations were used for the recovery studies (Table 3) , the crystalline compound may act differently from native blood samples. The reason for this discrepancy and for the greater variation when using crystalline l-homocystine is unknown; in part, however, it seems to be related to reduction of the disulfide bond of the commercial product. If the crystalline compound is a bit more difficult to reduce, slightly less l-homocysteine will be available and subsequently less SAH will be generated than when native blood samples are used. However, given differences observed between commercial l-homocystine products, the purity of the crystalline compound also seems to be of importance. Although not successful, we tried varying several assay conditions (including concentrations of Ado and DTT, amount of enzyme, and pH) to address this problem. Given these problems, as well as the lower stability of Hcy calibrators prepared from the crystalline products, we have been using SAH calibrators in the assay.
The use of SAH in the recovery experiments tests the immunoassay part of the presented assay. For evaluation of all steps in the procedure, including the enzymatic conversion, l-homocystine should be used. Because the enzyme conversion step of Hcy to SAH by SAHase is not controlled by using SAH as calibrator, plasma or serum control samples with known tHcy concentrations should be assayed together with the calibrators and samples.
Although the tHcy results obtained correlate well with HPLC results, the method presented measures slightly lower concentrations than the HPLC method-on average, 5-10% lower. This difference generally reflects the lack of standardization in tHcy assays; as long as this is the case, results from HPLC and the enzyme immunoassay presented should not be used interchangeably. The observed difference between the methods could be a result of the purity of the chemicals used and the preparation of calibrators. Given the specificity of SAHase reaction, enantiomeric purity of the Hcy calibrators is essential. However, the similarities of the calibration curves obtained with either SAH or crystalline l-homocystine suggest that this is not an important source of error. Another possibility is related to the unique chemical characteristics of Hcy in plasma/serum, of which almost all is protein-bound in thawed plasma samples. Thus, it is possible that the reduction of oxidized Hcy species, the enzyme conversion, and the immunoassay differ between plasma/serum and water-based calibrators. However, this is not supported by the recovery experiments, which indicate equal performance with plasma samples and water-based calibrators. In any case, slope differences have also been reported between chromatographic methods [13] , and further studies are therefore necessary to establish good interlaboratory correlation for the Hcy analyte.
We used thimerosal to inhibit SAHase before adding Adoase to remove excess Ado. Although more specific inhibitors and inactivators of SAHase have been tested, among them 2-chloroadenosine, aristeromycin, eritadenine, adenosine dialdehyde, and adenine arabinofuranoside [14] , they either competed with the anti-SAH antibody or failed to inactivate the enzyme completely within acceptable incubation times or concentrations (data not shown).
Cross-reactivity studies have shown that the monoclonal anti-SAH antibody does cross-react somewhat with Ado. To eliminate this problem, we used Adoase to convert the excess Ado into inosine, which does not cross-react with the antibody. The specificity of the anti-SAH antibody was found to be directed against the Ado residue/thio-ether region of SAH. High concentrations of both methionine and cysteine, as well as Hcy alone, do not cross-react with the antibody, nor does cystathionine. The fact that only SAM was found to affect the determination of Hcy is explained by the structural resemblance of this compound to SAH and the corresponding recognition by the anti-SAH antibody. Although SAM in concentrations Ͼ10 mol/L did show an effect, this is Ͼ50 -100 times greater than the concentration usually found in human plasma [15] . Similarly, endogenous SAH does not interfere because of its low concentration in human plasma [15] .
Determination of tHcy requires special care in handling the blood samples. The concentrations of tHcy show a time-and temperature-dependent increase in wholeblood samples related to a continuous production and release of Hcy from blood cells [9, 11] . Artifactual increases are low when the blood samples are centrifuged and plasma separated within 1 h after collection. Because addition of anticoagulants such as EDTA or heparin allows immediate centrifugation, this is the main reason for recommending plasma rather than serum samples for the analysis of tHcy in blood.
Fluoride has been suggested as an additive to blood samples to prevent cells from producing and leaking intercellular Hcy into the plasma after collection [11, 12] . However, the decrease in measured tHcy in collection tubes containing added fluoride/heparin, in comparison with those containing EDTA, makes it necessary to investigate the use of this type of vial in more detail.
Unlike all chromatographic methods, the present method makes use of inexpensive apparatus available in many laboratories. The method therefore serves as an attractive alternative to HPLC analysis, both in routine and research laboratories. This new analytical method should help clinical laboratories in the diagnosis of vitamin deficiency as well as benefit clinical researchers in large population-based studies on the potential use of homocysteine as an independent risk factor for premature cardiovascular disease.
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